Equities

Legend Biotech Corp

Legend Biotech Corp

Actions
  • Price (USD)40.03
  • Today's Change-0.92 / -2.25%
  • Shares traded2.58m
  • 1 Year change-38.74%
  • Beta0.0751
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

  • Revenue in USD (TTM)455.99m
  • Net income in USD-285.01m
  • Incorporated--
  • Employees2.20k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ultragenyx Pharmaceutical Inc522.75m-558.99m4.65bn1.28k--13.40--8.90-6.46-6.466.023.760.37661.916.06409,674.80-40.27-33.35-50.12-38.3086.2593.13-106.93-154.712.65--0.00--19.5253.1814.25--62.91--
Alkermes Plc1.51bn502.58m4.67bn2.10k9.783.618.603.102.951.968.837.990.67881.324.24716,724.3022.671.3428.901.7483.1783.3233.392.123.03--0.18270.0049.618.741,665.99---7.10--
Biohaven Ltd0.00-746.61m5.26bn239.00--12.87-----9.15-9.150.004.160.00----0.00-137.07---176.64--------------0.00------28.43------
Crinetics Pharmaceuticals Inc1.39m-258.54m5.42bn290.00--5.79--3,914.07-3.77-3.770.020110.470.0023--0.41574,775.86-41.16-42.53-44.29-45.36-----18,257.91-5,446.39----0.00---15.2810.57-30.88--34.65--
Arcellx Inc155.82m-40.42m5.54bn130.00--11.52--35.55-0.7196-0.71962.988.950.226----1,198,600.00-5.86-38.82-7.56-45.41-----25.94-339.38----0.022------62.53--113.86--
Krystal Biotech Inc241.52m52.37m5.74bn229.00112.956.4896.6323.771.771.778.2130.800.27251.514.531,054,664.005.91-11.506.33-12.0192.55--21.68-492.857.76--0.00------107.81--39.49--
Ionis Pharmaceuticals Inc803.07m-358.81m6.19bn927.00--9.34--7.71-2.45-2.455.504.200.2670.386410.02866,306.40-11.93-6.30-13.52-7.4498.7098.75-44.68-21.238.82--0.6587--34.105.60-35.80--11.83--
Nuvalent Inc0.00-173.59m6.23bn115.00--9.69-----2.78-2.780.009.840.00----0.00-31.08---32.81--------------0.00-------54.20------
Blueprint Medicines Corp434.41m-128.05m6.41bn638.00--20.43--14.74-2.11-2.116.924.930.37690.89548.11663,227.50-11.11-29.92-13.84-34.0697.01---29.48-116.653.27-10.800.5525--22.2241.149.06--4.85--
Cytokinetics, Inc.3.22m-576.40m6.82bn423.00------2,119.26-5.39-5.390.0301-0.1180.003--2.357,609.93-52.96-43.14-57.95-47.22-----17,906.24-540.47---14.271.02---92.04-24.89-35.30--9.76--
Legend Biotech Corp (ADR)455.99m-285.01m7.38bn2.20k--6.33--16.18-1.57-1.572.516.330.244610.6332.42253,328.30-15.29-37.71-17.63-47.1960.28---62.50-286.514.78--0.2263--143.7042.15-16.11--1.57--
Viking Therapeutics Inc0.00-99.15m7.63bn33.00--8.37-----0.937-0.9370.008.180.00----0.00-15.02-21.91-15.47-23.04------------0.00-------24.73------
Madrigal Pharmaceuticals Inc76.81m-518.67m7.65bn376.00--9.84--99.58-25.07-25.073.7135.640.1172----204,289.90-79.11-62.09-100.35-74.8196.37---675.24--5.93--0.1309-------26.50--132.01--
Exact Sciences Corp2.69bn-214.04m9.53bn6.50k--2.975,226.403.54-1.17-1.1714.7017.350.40895.4011.60414,204.30-3.25-9.71-3.58-10.6072.9674.10-7.95-28.211.93--0.4459--19.9340.6367.26---3.71--
Data as of Nov 08 2024. Currency figures normalised to Legend Biotech Corp's reporting currency: US Dollar USD

Institutional shareholders

32.40%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 202416.01m8.80%
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 202411.49m6.31%
RA Capital Management LPas of 30 Jun 20247.51m4.13%
HHLR Advisors Ltd.as of 30 Jun 20246.64m3.65%
Westfield Capital Management Co. LPas of 30 Jun 20244.77m2.62%
BlackRock Fund Advisorsas of 30 Jun 20243.45m1.90%
Wellington Management Co. LLPas of 30 Jun 20242.62m1.44%
Janus Henderson Investors US LLCas of 30 Jun 20242.33m1.28%
Capital Research & Management Co. (International Investors)as of 30 Jun 20242.16m1.19%
Massachusetts Financial Services Co.as of 30 Jun 20241.96m1.08%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.